Completed PHASE1 INTERVENTIONAL 6-arm NCT00856713

Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers

A Study in Healthy Volunteers and Patients With Liver Cirrhosis to Assess the Effects of Age, Gender, and Stable Liver Disease on the Clearance of Cholyl-Lysyl-Fluorescein (NRL972) as an in-Vivo Marker of Liver Function in Man

Sponsor: Norgine

Conditions Hepatic Cirrhosis

Interventions NRL972

Updated 5 times since 2017 Last updated: Mar 5, 2009 Started: Mar 31, 2006 Primary completion: Aug 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hepatic Cirrhosis and is currently completed. Norgine leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Norgine

Data source: Norgine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sofia, Bulgaria